A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
12/2002
12/11/2002	CN1095663C Method for inhibiting LDL oxidation and atherosclerosis
12/10/2002	US6492552 Disulfide derivatives useful for treating allergic diseases
12/10/2002	US6492520 Substituted pyrido-or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
12/10/2002	US6492424 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders
12/10/2002	US6492408 Peptidomimetic inhibitors of intercellular adhesion molecules binding to leukointegrins, such as lfa-1 and mac-1
12/10/2002	US6492406 Pharmaceutically active compounds
12/10/2002	US6492403 Methods of treating C1s-mediated diseases and conditions and compositions thereof
12/10/2002	US6492401 Sodium hydrogen exchanger type 1 inhibitors; reducing perioperative myocardial tissue damage
12/10/2002	US6492393 Compounds useful as anti-inflammatory agents
12/10/2002	US6492379 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
12/10/2002	US6492376 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
12/10/2002	US6492372 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
12/10/2002	US6492365 Microsomal triglyceride transfer protein
12/10/2002	US6492362 Compounds and compositions as cathepsin S inhibitors
12/10/2002	US6492348 Adenosine derivatives
12/10/2002	US6492341 Preparation of fagopyritols and uses therefor
12/10/2002	US6492337 Administering a ceramide
12/10/2002	US6492167 Membrane protein for use in the treatnment of diabetes, hypotension, endocrine defects
12/10/2002	US6492157 Methods are provided for the treatment of conditions associated with cells proliferation, cells differentiation and cell survival. in particular, the dual-specificity phosphatase dsp-9, and polypeptide variants thereof that
12/10/2002	US6492129 Fragments comprising the n-terminal region of connective tissue growth factor (ctgf); screening for inhibitors or stimulators of ctgf
12/10/2002	US6491933 Personal care articles comprising hotmelt compositions
12/10/2002	US6491913 For diagnosis and therapy of sulphamidase deficiency
12/10/2002	US6491907 Genetic engineered chimera particles comprising capsids from adeno-associated virus and genome inverted terminal repeat sequences as vectors for supplying and expressing nucleotide sequence in cells
12/10/2002	US6491903 Particles comprising amphiphilic copolymers
12/10/2002	CA2208792C Substituted indazole derivatives
12/10/2002	CA2196085C Mhc complexes and uses thereof
12/10/2002	CA2054268C Nutritional composition
12/10/2002	CA1341408C Method for treating and preventing loss of bone mass
12/09/2002	WO2002004403A1 Biphenylcarboxylic acid amides, production thereof and use thereof as medicaments
12/09/2002	CA2412116A1 Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
12/08/2002	CA2817619A1 Methods of administering anti-tnf.alpha. antibodies
12/08/2002	CA2385745A1 Methods of administering anti-tnf.alpha. antibodies
12/05/2002	WO2002097437A1 Assay for beta cell toxic macrolides
12/05/2002	WO2002097120A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof
12/05/2002	WO2002097063A1 Production of bioavailable folic acid
12/05/2002	WO2002097060A2 Carbohydrate-associated proteins
12/05/2002	WO2002097046A2 B7 related protein-2 molecules and uses thereof
12/05/2002	WO2002097044A2 Alternative splice forms of proteins as basis for multiple therapeutic modalities
12/05/2002	WO2002097037A2 Melanin-concentrating hormone analogs
12/05/2002	WO2002097032A2 Proteins associated with cell growth, differentiation, and death
12/05/2002	WO2002097030A2 Peptides derived from neural thread proteins and their medical use
12/05/2002	WO2002096952A2 Conjugate of a transport protein and a protein for modulation of notch signalling
12/05/2002	WO2002096943A1 Stat6-activating genes
12/05/2002	WO2002096932A1 Transporters and ion channels
12/05/2002	WO2002096927A2 Ribozyme based treatment of female reproductive diseases
12/05/2002	WO2002096926A1 Modulators of pharmacological agents
12/05/2002	WO2002096911A1 Novel heteroaryl-diazabicyclo-alkanes as cns-modulators
12/05/2002	WO2002096909A1 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors
12/05/2002	WO2002096905A1 Thiazole compounds useful as inhibitors of protein kinases
12/05/2002	WO2002096904A1 Novel heterocyclic derivatives and medicinal use thereof
12/05/2002	WO2002096895A1 Oxazol/ thiazol-derivatives activators of the hppar-alpha receptor
12/05/2002	WO2002096894A1 Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
12/05/2002	WO2002096893A1 Process for preparing a thialzole ppar-ligand and polymorphs thereof
12/05/2002	WO2002096883A1 Tricyclic compounds useful as angiotensin ii agonists
12/05/2002	WO2002096879A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
12/05/2002	WO2002096876A1 Carbamate and oxamide compounds as inhibitors of cytokine production
12/05/2002	WO2002096867A2 Inhibitors of protein kinase for the treatment of disease
12/05/2002	WO2002096866A2 Thiolalkyl benzoic acid derivatives
12/05/2002	WO2002096864A1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments
12/05/2002	WO2002096863A1 New phenylalkyloxy-phenyl derivatives
12/05/2002	WO2002096453A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin
12/05/2002	WO2002096449A1 Carbohydrate modifying agent and drinks containing the modifying agent
12/05/2002	WO2002096445A2 Food compositions for reducing insulin resistance
12/05/2002	WO2002096427A1 Pyrimidine derivatives as selective inhibitors of cox-2
12/05/2002	WO2002096426A1 Hydantion derivatives as inhibitors of matrix metalloproteinases
12/05/2002	WO2002096419A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
12/05/2002	WO2002096414A1 Medicament containing an effector of the glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy
12/05/2002	WO2002096410A1 Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
12/05/2002	WO2002096408A1 Coenzyme q and eicosapentaenoic acid (epa)
12/05/2002	WO2002096402A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a biguanide drug
12/05/2002	WO2002096399A1 Lipolysis accelerator, cosmetic skin preparation for body weight reduction and food or beverage composition each containing the same, and method for reducing body weight and medicinal use each based on activity of the same
12/05/2002	WO2002096398A2 Medicament containing an effector of the glutathione metabolism together with $g(a)-lipoic acid for treating diabetes mellitus
12/05/2002	WO2002096393A1 Anorexic composition comprising calcium acetate
12/05/2002	WO2002096363A2 Method for treating fibrotic diseases or other indications
12/05/2002	WO2002096362A2 Method for treating fibrotic diseases or other indications vi
12/05/2002	WO2002096360A2 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
12/05/2002	WO2002096358A2 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
12/05/2002	WO2002096357A2 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
12/05/2002	WO2002096353A2 Polymer controlled induced viscosity fiber system and uses thereof
12/05/2002	WO2002096224A1 Oral composition comprising an extract from the bark of albizzia myriophylla
12/05/2002	WO2002096223A1 Dual viscosity fiber system and uses thereof
12/05/2002	WO2002096219A2 Acid controlled viscosity fiber system and uses thereof
12/05/2002	WO2002096203A1 Stem cell differentiation
12/05/2002	WO2002081415A3 Method for inhibiting metap2
12/05/2002	WO2002076400A3 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
12/05/2002	WO2002070557A3 Nuclear hormone receptor ligand binding domain
12/05/2002	WO2002068470A3 Interferon-alpha induced gene
12/05/2002	WO2002062798A3 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
12/05/2002	WO2002036073A3 Receptor antagonist-lipid conjugates and delivery vehicles containing same
12/05/2002	WO2002028902A3 Nectin polypeptides, polynucleotides, methods of making and use thereof
12/05/2002	WO2002013862A3 Method and composition for altering a b cell mediated pathology
12/05/2002	WO2002013861A3 Method and composition for altering a t cell mediated pathology
12/05/2002	WO2002009685A1 Preparation with vascular protective and anti-oxidative effect and use thereof
12/05/2002	WO2001094605A3 Recombinant aav vectors for gene therapy of obesity
12/05/2002	WO2001093840A2 Ligands of integrin receptors
12/05/2002	US20020183527 Process for the preparation of amorphous atorvastatin
12/05/2002	US20020183524 Preparations and use of an Ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
12/05/2002	US20020183507 Novel human GABA receptor proteins and polynucleotides encoding the same
12/05/2002	US20020183399 Method and compositions for treating rosacea
12/05/2002	US20020183384 Administering sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt for therapy of disease or a disorder responsive to inhibition of nuclear factor- kappa B (NF- kappa B)

1 ... 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 ... 1298